
News|Articles|October 1, 2006
High-dose statin therapy displays benefit in preventing cardiovascular events compared with standard doses
Intensive lipid lowering with high-dose 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) provides a significant benefit over standard-dose statin therapy in preventing nonfatal cardiovascular outcomes and also may reduce the incidence of cardiovascular death, according to results of a meta-analysis published in the Journal of the American College of Cardiology.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Spain can offer a healthcare lesson to the United States
2
MHE Week in Review – COVID Shingles Risk, FDA Removes Menopause Therapy Warning and More
3
Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer
4
Two studies underscore need for more effective, bladder-sparing therapies in high-risk cancer
5

















































